Final FY 2026 appropriations bill sustains ID funding, holds Administration accountable

The FY 2026 Labor, Health and Human Services, Education and Related Agencies appropriations bill provides level funding with FY 2025 to maintain most key domestic and global infectious diseases programs, including top IDSA priorities like the Centers for Disease Control and Prevention’s Antibiotic Resistance Solutions Initiative and the National Institute of Allergy and Infectious Diseases. In the current political environment, this bill is a victory and demonstrates the power of IDSA members’ tenacious advocacy.

Congress heeded calls from IDSA members to include language in the bill aimed at reining in harmful Administration policies, including the following provisions:

• Directs the Administration to maintain enough staff to support agency and program responsibilities
• Prohibits changes to current National Institutes of Health indirect cost policy 
• Requires notification before changes to NIH grants
• Maintains current policy on funding for international NIH grantees
• Prohibits forward funding of multiyear NIH grants 

IDSA continues to strongly encourage Congress to make deeper investments in ID infrastructure in FY 2027, especially to better support the ID workforce and combat antimicrobial resistance. 

Thank you to the IDSA members whose advocacy in our most challenging year yet made these victories possible. We will continue to need the voice of every IDSA member as we advocate for FY 2027 funding.

Information on funding for HIV programs can be found here.

Additional details on the funding levels for specific agencies and programs in the appropriations bills are below. 

Labor, Health and Human Services appropriations bill

• $47.2 billion in overall funding for NIH, a $400 million increase over FY 2025
• $9.2 billion in overall funding for CDC, level with FY 2025
• $197 million for CDC’s Antibiotic Resistance Solutions Initiative, level funding
• $6.6 billion for NIAID at NIH, a $23 million increase; this includes $565 million for antimicrobial resistance research, level funding
• $1.050 billion for the Biomedical Advanced Research and Development Authority, a $35 million increase over FY 2025
• $692.843 million for the Center for Global Health, the same as FY 2025, and
• $293 million for Global Health Protection
• $24 million in funding for the National Healthcare Safety Network at CDC, level funding
• $40 million in funding for the Advanced Molecular Detection initiative at CDC, level funding
• $23 million for infectious diseases and opioid activities at CDC, level funding
• $95.162 million for NIH’s Fogarty International Center, level funding
• $682 million for CDC’s Immunizations Program, level funding 

State Department global health programs:

• $4.633 billion for the President’s Emergency Plan for AIDS Relief, an increase of $238.8 million over FY 2025 funding, to account for the U.S. contribution to UNAIDS and repurposed funding from former USAID global HIV programming
• $1.25 billion for the U.S. contribution to the Global Fund to Fight AIDS, TB and Malaria, a cut of $400 million over FY 2025 funding but aligned with the Trump Administration’s pledge to the Global Fund
• $378.72 million for global TB programming, a cut of $15.78 million over FY 2025 funding
• $795 million for global malaria programming, flat funded from FY 2025
• $615.61 million for global health security, a cut of $84.4 million over FY 2025

About IDSA
The Infectious Diseases Society of America is a global community of 13,000-plus clinicians, scientists and public health experts working together to solve humanity’s smallest and greatest challenges, from tiny microbes to global outbreaks. Rooted in science, committed to health equity and driven by curiosity, our compassionate and knowledgeable members safeguard the health of individuals, our communities and the world by advancing the treatment and prevention of infectious diseases. Visit idsociety.org to learn more.